May 1, 2018

Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer

Read More

Developing new medicines to treat diseases characterized by mineral imbalances in the body

There are over 7,000 rare diseases recognized by the medical community—a disproportionate number of which affect infants and young children. We are singularly focused on developing new, potentially disease-modifying therapies for these children and their families.

Discover How